Back
DELHI HIGH COURT
C.HARI SHANKAR
Novartis AG – Appellant
Versus
Zydus Healthcare Limited – Respondent
| Table of Content |
|---|
| 1. overview of the plaint and litigation context (Para 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11) |
| 2. defendants' arguments against the plaint and reliance on investigation report (Para 13 , 14 , 15 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27) |
| 3. the legal standards for maintaining a quia timet action (Para 28 , 37 , 38 , 39 , 40 , 41 , 47) |
| 4. judicial analysis of the cause of action and its requirements (Para 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 46 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72) |
| 5. conclusion; dismissal of the application (Para 74 , 75) |
JUDGMENT
IA 6051/2022 in CS(COMM) 681/2021
1. I proceed to dispose of IA 6051/2022, filed by the defendants Zydus Healthcare Ltd. and Cadila Healthcare Ltd. under Order VII Rule 11 of the Code of Civil Procedure, 1908 (CPC), whereby the defendants seek rejection of the plaint in CS (Comm) 681/2021, instituted by Novartis AG and Novartis Healthcare Pvt. Ltd..
Facts
2. Novartis asserts Indian Patent IN 229051, titled "Pharmaceutical Compositions comprising Valsartan and NEP inhibitors".
3. The suit patent, it is asserted, consists
An indispensable Tool for Legal Professionals, Endorsed by Various High Court and Judicial Officers
Please visit our Training & Support
Center or Contact Us for assistance
Scan Me!
India’s Legal research and Law Firm App, Download now!
For Daily Legal Updates, Join us on :
Back to top
